

# Tumor de Sítio Primário Desconhecido

## **PCE**

Paclitaxel: 200 mg/m<sup>2</sup> IV D1

Carboplatina: AUC 6 IV D1

Etoposide: 50 mg alternando com 100 mg VO D1-10  
a cada 21 dias

Ref. (1)

## **EP**

Etoposide: 80 a 120 mg/m<sup>2</sup> IV D1-5

Cisplatina: 60 a 100 mg/m<sup>2</sup> IV D1

a cada 21 dias

Ref. (2, 4)

## **PEB**

Cisplatina: 20 mg/m<sup>2</sup> IV D1-5

Etoposide: 100 mg/m<sup>2</sup> IV D1-5

Bleomicina: 30 unidades IV D1, 8 e 15

a cada 21 dias

Ref. (3)

## **GC**

Gencitabina 1250mg/m<sup>2</sup> IV D1 e D8

Cisplatina 100mg/m<sup>2</sup> IV D1

a cada 21 dias

Ref. (5)

## **IC**

Irinotecano 150 mg/m<sup>2</sup> IV D1

Cisplatina 80mg/m<sup>2</sup> IV D1

a cada 21 dias

Ref. (5)

## **PCF**

Paclitaxel 200mg/m<sup>2</sup> IV em 1 hora D1 e D22

Carboplatina AUC 6 IV D1 e D22  
5-Fluorouracil: 225mg/m<sup>2</sup>/dia IV em 24 horas, D1 a D35  
a cada 6 semanas Ref. (6)

### **GD**

Gencitabina: 1000mg/m<sup>2</sup> IV D1 e D8  
Docetaxel: 75 mg/m<sup>2</sup> IV D8 em 1 hora  
a cada 21 dias Ref. (7)

### **DC**

Docetaxel: 75mg/m<sup>2</sup> IV D1  
Cisplatina: 75mg/m<sup>2</sup> IV D1

### **OU**

Docetaxel: 60mg/m<sup>2</sup> IV D1  
Carboplatina: AUC 6 IV D1  
a cada 21 dias Ref. (8)

### **CP**

Paclitaxel: 200mg/m<sup>2</sup> IV D1 em 3 horas D1  
Carboplatina: AUC 6 IV D1  
a cada 21 dias Ref. (9)

### **GCP**

Gencitabina: 1000mg/m<sup>2</sup> IV D1 e D8  
Paclitaxel: 200mg/m<sup>2</sup> IV D1  
Carboplatina: AUC 6 IV D1  
a cada 21 dias Ref. (10)

### **CAE**

Carboplatina: 400mg/m<sup>2</sup> IV D1  
Adriamicina: 50mg/m<sup>2</sup> IV D1  
Etoposide: 100mg/m<sup>2</sup> IV D1 a D3  
a cada 21 dias Ref. (11)

**GC**

Gencitabina: 1000mg/m<sup>2</sup> IV D1 e D8

Carboplatina: AUC 5 IV D8

a cada 21 dias

Ref. (12)

**GCC**

Carboplatina: AUC 5 IV D1

Gencitabina: 1000mg/m<sup>2</sup> IV D1 e D8

Capecitabina: 1600mg/m<sup>2</sup> VO D1 a D14

a cada 21 dias

Ref. (13)

**IC**

Irinotecano: 60mg/m<sup>2</sup> IV D1,8 e 15

Carboplatina: AUC 5 IV D1

a cada 28 dias

Ref. (14)

**GEMZAR**

Gencitabina: 1000mg/m<sup>2</sup> D1,D8 e D15 IV a cada 28 dias

Ref. (15)

**GI**

Gencitabina: 1000mg/m<sup>2</sup> IV D1 e D8

Irinotecano: 100mg/m<sup>2</sup> IV D1 e D8

a cada 21 dias

Ref. (16)

**OC**

Oxaliplatina: 130mg/m<sup>2</sup> IV D1

Capecitabina: 1000mg/m<sup>2</sup> duas vezes ao dia VO D1 a D14

a cada 21 dias

Ref. (17)

**GCP**

Cisplatina: 35mg/m<sup>2</sup> IV D1 e D8

Gencitabina: 1000mg/m<sup>2</sup> IV D1 e D8

Paclitaxel: 70mg/m<sup>2</sup> IV D1 e D8

a cada 21 dias

Ref. (18)

## **GCV**

Cisplatina: 35mg/m<sup>2</sup> IV D1 e D8

Gencitabina: 1000mg/m<sup>2</sup> IV D1 e D8

Vinorelbina: 25mg/m<sup>2</sup> IV D1 e D8

a cada 21 dias

Ref. (18)

1. Hainsworth JD, Erlance JB, Kalman LA, Schreeder MT, Greco FA. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, extended-schedule etoposide. *J Clin Oncol* 1997;15:2385–2393.
2. Longeval E, *et al.* Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma adenocarcinoma. A study by the EORTC lung cancer working party. *Cancer* 1982;50:2751–2756.
3. Hainsworth JD, *et al.* Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. *J Clin Oncol* 1992;10:912–922.
4. Sheperd FA. Treatment of advanced non-small cell lung cancer. *Semin Oncol.* 1994; 21(suppl 7): 7-18.
5. Culine S; Lortholary A; Voigt JJ; Bugat R; Theodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Allouache J; Goupil A; Negrier S; Viala J; Petrow P; Bouzy J; Laplanche A; Fizazi K. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). *J Clin Oncol* 2003 Sep 15;21(18):3479-82.
6. Hainsworth JD, Burris HA 3rd, Meluch AA, Baker MN, Morrissey LH, Greco FA. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial. *Cancer.* 2001 Aug 1;92(3):642-9.

7. Pouessel D; Culine S; Becht C; Ychou M; Romieu G; Fabbro M; Cupissol D; Pinguet F. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. *Cancer* 2004 Mar 15;100(6):1257-61.
8. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Greco FA; Erland JB; Morrissey LH; Burris HA 3rd; Hermann RC; Steis R; Thompson D; Gray J; Hainsworth JD. *Ann Oncol* 2000 Feb;11(2):211-5.
9. Briasoulis E; Kalofonos H; Bafaloukos D; Samantas E; Fountzilias G; Xiros N; Skarlos D; Christodoulou C; Kosmidis P; Pavlidis Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. *J Clin Oncol* 2000 Sep;18(17):3101-7.
10. Greco FA; Burris HA 3rd; Litchy S; Barton JH; Bradof JE; Richards P; Scullin DC Jr; Erland JB; Morrissey LH; Hainsworth JD. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. *J Clin Oncol* 2002 Mar 15;20(6): 1651-6.
11. Piga A, Nortilli R, Cetto GL, Cardarelli N, Fedeli SL, Fiorentini G, D'Aprile M, Giorgi F, Parziale AP, Contu A, Montironi R, Gesuita R, Carle F, Cellerino R. Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site. *Br J Cancer*. 2004 May 17;90(10):1898-904.
12. Pittman KB; Olver IN; Koczwara B; Kotasek D; Patterson WK; Keefe DM; Karapetis CS; Parnis FX; Moldovan S; Yeend SJ; Price TJ Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. *Br J Cancer*. 2006 Nov 20;95(10):1309-13. Epub 2006 Oct 31.
13. Schneider BJ; El-Rayes B; Muler JH; Philip PA; Kalemkerian GP; Griffith KA; Zalupski MM. Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. *Cancer*. 2007 Aug 15;110(4):770-5.
14. Yonemori K; Ando M; Yunokawa M; Hirata T; Kouno T; Shimizu C; Tamura K; Katsumata N; Hirakawa A; Matsumoto

- K; Yamanaka Y; Arioka H; Fujiwara Y. Irinotecan plus carboplatin for patients with carcinoma of unknown primary site. *Br J Cancer*. 2009 Jan 13;100(1):50-5. Epub 2008 Dec 16.
- 156.** Hainsworth JD; Burris HA 3rd; Calvert SW; Willcutt NT; Scullin DC Jr; Bramham J; Greco FA. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. *Cancer Invest* 2001;19(4):335-9.
- 16.** Hainsworth JD; Spigel DR; Raefsky EL; Kuzur ME; Yost K; Kommor M; Litchy S; Greco FA. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial. *Cancer* 2005 Nov 1;104(9):1992-7.
- 17.** Hainsworth JD; Spigel DR; Burris HA 3rd; Shipley D; Farley C; Macias-Perez IM; Barton J; Greco FA. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. *Cancer*. 2010 May 15;116(10):2448-54.
- 18.** Palmeri S; Lorusso V; Palmeri L; Vaglica M; Porta C; Nortilli R; Ferrau F; Comella G; Massidda B; Danova M. Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II study. *Cancer*. 2006 Dec 15;107(12):2898-905.